BioNTech vaccine agent, Fosun Pharma, seeks more global sales through M&A opportunities, push into new markets

• Company aims to raise offshore sales to 40 per cent of group revenue over five years, from about 27 per cent in 2020
• Company intends to launch three to four biosimilars and innovative drugs this year, and more in 2022 as additional candidates pass through R&D phase